You are here
Marialaura Amadio, Doctorate
Department of Drug Sciences; Pharmacology Section; University of Pavia; Pavia - Italy
Areas of Interest:
neurodegeneration, aging, oxidative stress, retinal diseases, RNA-binding proteins, Protein kinase C
Biography & Research:
After degree in Pharmacy in 2000, Marialaura Amadio obtained specialization in Applied Pharmacology in 2004, and PhD in Biomolecular Sciences and Biotechnologies in 2007. During her training, she received fellowships and spent periods in the following national and international centres: “Blanchette Rockefeller Neurosciences Institute”, Rockville (USA); Institute of Human Virology, University of Maryland, Baltimore (USA); Laboratory of Metabolomics and Systems Biology, European Centre of Magnetic Resonance, University of Florence, Italy; “Neuroinflammation Research Center”, Department of Psychiatry, Mount Sinai School of Medicine, New York (USA). At the present, Marialaura is Aggregate Professor at the Dept. of Drug Sciences, Pharmacology Section, University of Pavia, where she has academic assignments for the courses entitled “Applied Pharmacology” and “The new antitumor drugs” at the School of Pharmacy and School of Biotechnologies. She collaborates extensively with various national and international scientists, especially in Finland, where in 2015 she spent a short period as Visiting Professor at the Department of Ophthalmology of the University of Eastern Finland, in Kuopio. She is member of the European Association for Vision and Eye Research. She is currently contributing as the Lead Guest Editor of the Special Issue on “Molecular Mechanisms Underlying Age-related Ocular Diseases” in Oxidative Medicine and Cellular Longevity. Her research mainly focuses on the biology of aging and retinal diseases. Her interest is for cellular and molecular pharmacology, in particular on the role of the RNA-binding ELAV proteins in the post-transcriptional control of gene expression in several physio-pathological contexts (such as memory, Alzheimer’s disease, oxidative stress, diabetic retinopathy and age-related macular degeneration). Her studies also point on the possibility to modulate the ELAV cascade up-stream, through the activation/inhibition of PKC, and directly by the use of ELAV-like compounds or siRNA technology. Another more recent field of interest is the autophagic process and its role in neurodegeneration. She is author of 40 peer-reviewed articles and one chapter on English book.